NEWS
undefined

undefined

Lidocaine Hydrochloride (Y20220001197) has been registered in CDE with the status of “A”

Lidocaine Hydrochloride (Y20220001197) has been registered in CDE with the status of “A”

Recently, ’the API Lidocaine Hydrochloride (Y20220001197) held by Jiudian HongYang has been registered in CDE with the status of “A”.

31

2024

/

05

Jiudian Pharmaceutical participates in the 88th PHARMCHINA and 90th APICHINA

Jiudian Pharmaceutical participates in the 88th PHARMCHINA and 90th APICHINA

From May 15th to 17th , the 88th PHARMCHINA and 90th APICHINA was held in Shanghai China.PHARMCHINA is a professional trade and exchange exhibition platform of the pharmaceutical and health industry.

17

2024

/

05

Jiudian Scholarship Donation Ceremony was held in Xiangtan University

Jiudian Scholarship Donation Ceremony was held in Xiangtan University

On the occasion of the 50th anniversary of Xiangtan University's re-establishment, Jiudian Pharmaceutical donated 250,000 yuan to Xiangtan University and injected it into the "Xiangtan University Jiudian Pharmaceutical Scholarship Fund" to support poverty students in the School of Chemistry.

21

2024

/

03

Hunan Jiudian Pharmaceutical have Market Authorization of Potassium Sulphate API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Potassium Sulphate API from NMPA

In the middle of March, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Potassium Sulphate API from NMPA.

18

2024

/

03

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

Hunan Jiudian Pharmaceutical have Ecovadis Bronze at the beginning of 2024

06

2024

/

03

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen Peplib Biotech.

Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen PepLib Biotech in Changsha China on Feb 28, 2024.

29

2024

/

02

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of dapoxetine hydrochloride, celecoxib and Nicorandil API from NMPA

In Feb, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of dapoxetine hydrochloride and celecoxib API from NMPA.

03

2024

/

02

Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA

Jiudian Pharmaceutical have drug license of Ebastine oral solution from NMPA

01

2024

/

02

< 1...12131415 >

Hunan Jiudian

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China     TEL. 0086-731-88220222     

1

Business license

Powered by：CEglobal   Privacy policy